This viewpoint argues that the rise of GLP-1 therapies should reinforce, not replace, the need for primary obesity prevention. While these medications improve outcomes for individuals, they do not address the environmental, social, and commercial drivers of obesity. The authors call for sustained investment in prevention policies alongside equitable access to effective treatments.
Holm, S., Tena-Sempere, M., Koutsouris, D., Dedoussis, G. V., Wagner, K.-H., Arranz, S., Froguel, P., Bohn, T., Oliveira, P. J., & Lakerveld, J., on behalf of OBEClust. (2026). The case for primary prevention of obesity in the era of GLP-1 therapies. The Lancet Regional Health – Europe, 101679. https://doi.org/10.1016/j.lanepe.2026.101679